Refine by
Locations
- USA
- Alabama
- Alaska
- Arizona
- Arkansas
- California
- Colorado
- Connecticut
- Delaware
- District Of Columbia
- Florida
- Georgia (Us)
- Hawaii
- Idaho
- Illinois
- Indiana
- Iowa
- Kansas
- Kentucky
- Louisiana
- Maine
- Maryland
- Massachusetts
- Michigan
- Minnesota
- Mississippi
- Missouri
- Montana
- Nebraska
- Nevada
- New Hampshire
- New Jersey
- New Mexico
- New York
- North Carolina
- North Dakota
- Ohio
- Oklahoma
- Oregon
- Pennsylvania
- Rhode Island
- South Carolina
- South Dakota
- Tennessee
- Texas
- Utah
- Vermont
- Virginia
- Washington
- West Virginia
- Wisconsin
- Wyoming
Pre Clinical Study Equipment Supplied In Usa
198 equipment items found
by:OSSIO Inc based inWoburn, MASSACHUSETTS (USA)
Comprised of OSSIOfiber® Intelligent Bone Regeneration Technology, Fully integrates into native anatomy without adverse inflammation,, as proven in pre-clinical studies, Rivals performance of metal headless cannulated compression screws1, Can be trimmed to desired length ...
Manufactured by:Jointechlabs Inc. based inNorth Barrington, ILLINOIS (USA)
Based on our platform and technology, Jointechlabs is developing therapies for unmet medical needs. Our first therapeutic in clinical development JTL-T-01 is a proprietary injectable stem cell scaffold as a biologic therapy for osteoarthritis, for approval under the FDA’s fast-track program. JTL-T-01 has been designed as an autologous point-of-care therapy enabling the ...
by:LIXTE Biotechnology Holdings, Inc. based inPasadena, CALIFORNIA (USA)
Pre-clinical studies showed that LB-100 alone inhibits a spectrum of human cancers but when combined with standard cytotoxic drugs and/or radiation, LB-100 potentiates their effectiveness against hematologic and solid tumor cancers without enhancing toxicity. ...
Manufactured by:AGC Biologics based inBothell, WASHINGTON (USA)
Our ready-to-use platform capabilities are built on cell factories (up to 48L) and bioreactors (up to 200L) using adherent processes, designed entirely in-house. Our quality systems, GMP manufacturing scale and regulatory qualification allow us to meet both clinical and commercial demand. Moreover, our scale down capabilities provide flexible and cost-effective solutions for ...
Manufactured by:Pluristem Therapeutics Inc. based inHaifa, ISRAEL
PLX-Immune are cells that have been induced with tumor necrosis factor alpha (TNF-a) and interferon-gamma (IFN-g), to transiently alter their secretion profile. The product has been evaluated in pre-clinical studies and a peer-reviewed article in the journal Scientific Reports, from Nature, was published which examined the effect of the cells in ...
Manufactured by:CytomX Therapeutics, Inc. based inSouth San Francisco, CALIFORNIA (USA)
CX-188 is our wholly owned PD-1-targeting Probody therapeutic. As with anti-PD-L1 therapies, PD-1 monotherapy and combinations have been associated with significant toxicities. Our preclinical studies have shown that CX-188 has the potential for an improved therapeutic index relative to PD-1 antibodies. The IND for CX-188 was cleared by the FDA. Following a program and portfolio prioritization, ...
Manufactured by:Elpiscience based inShanghai, CHINA
ES004 is a potentially best-in-class antibody targeting pan-allele signal-regulatory protein alpha (SIRPα). SIRPα is an inhibitory receptor expressed only on myeloid cells and dendritic cells. Binding of CD47 to SIRPα delivers a “don’t eat me” signal to suppress phagocytosis. Tumor cells frequently overexpress CD47 to evade macrophage-mediated destruction. To ...
Manufactured by:EMulate Therapeutics, Inc. based inBellevue, WASHINGTON (USA)
Indolor Therapeutics is feasibility (phase I) trial ready for the treatment of acute and chronic pain by the application of specific pain-managing ulRFE fields, another expression of EMulate’s Therapeutic ...
by:Sorrento Therapeutics, Inc. based inSan Diego, CALIFORNIA (USA)
Sorrento utilizes a proprietary knock-out knock-in (KOKI) technology to modify normal healthy donor derived T cells to genetically engineer them to express the dimeric antigen receptor into T-cell receptor (TCR) alpha chain constant region (TRAC). In this manner, TRAC is knocked out and antigen is knocked into its locus. The Dimeric Antigen Receptor (DAR) utilizes a Fab instead of the scFv ...
Manufactured by:NeuroMD based inNorth Miami Beach, FLORIDA (USA)
The most advanced, FDA-cleared system to restore your lower back health and provide lasting pain relief. Equipped with pre-set, clinically studied NMES parameters, the Corrective Therapy Device® delivers proven electrical stimulation to correct the source of the pain. Get started on the path to relief during our biggest sale ever with savings ...
Manufactured by:Elpiscience based inShanghai, CHINA
LAG3 is an immune checkpoint receptor known to suppress T cell activation. We designed ES005 to block LAG3 ligands, including MHC class II and FGL1. Through unique epitope binding, ES005 is able to recognize human LAG3 with high affinity. In preclinical studies, ES005 inhibited tumor growth both as a monotherapy and in combination with a PD-1 ...
Manufactured by:Mirus Bio LLC based inMadison, WISCONSIN (USA)
TransIT-VirusGEN SELECT Transfection Reagent is designed to enhance delivery of packaging and transfer vector DNA to suspension and adherent HEK 293 cell types in order to increase production of recombinant lentivirus and adeno-associated virus (AAV). Key benefits of TransIT-VirusGEN SELECT Transfection Reagent include: Performance – Efficient DNA delivery for large-scale production of ...
by:Verb Biotics based inBoston, MASSACHUSETTS (USA)
Yso2 is a preclinical program targeting Crohn’s disease. It aims to develop Christensenella gut bacteria as a safe, efficient and groundbreaking oral biotherapy. YSOPIA has identified a lead candidate to relieve Crohn’s disease associated symptoms and slow down disease progression. Discover the articles we published in Scientific Reports: Relizani et al. 2022 and Kropp et al. 2021. ...
Manufactured by:AstraZeneca based inCambridge, UNITED KINGDOM
IVX-121 targets respiratory syncytial virus (RSV), a major cause of viral pneumonia for which no vaccine has been FDA approved. IVX-121 incorporates a stabilized prefusion F antigen licensed from NIAID/NIH (DS-Cav1; Science 2019). RSV F is known to undergo major structural changes that allow viral entry into the host cell, and during that process, critical protective epitopes are lost. Protein ...
Manufactured by:BriaCell Therapeutics Corp. based inWest Vancouver, BRITISH COLUMBIA (CANADA)
Early-Stage Preclinical Program: 30% of all human malignancies display activating RAS mutations with another 60% showing over-activity of Ras-signaling pathways. BriaCell’s novel, proprietary PKCδ inhibitors have shown activity against multiple RAS transformed tumors. This target has an attractive safety profile based on in vivo studies and knock out mouse studies. PKCδ also has ...
Manufactured by:Verax Biomedical, Incorporated based inMarlborough, MASSACHUSETTS (USA)
Verax is currently developing a version of its PGD test to address the risk of bacterial contamination in red blood cells. While the risk of red blood cell contamination is lower than the risk of platelet contamination, at 1:20,000, it is the second largest infectious risk for the nation’s blood supply and far exceeds the risk associated with transfusion-transmitted viruses such as HIV, ...
Manufactured by:Biopeptek Pharmaceuticals LLC based inMalvern, PENNSYLVANIA (USA)
Biopeptek is a leading manufacturer of synthetic peptide Active Pharmaceutical Ingredient (API). We offer custom APIs for pharmaceutical research & development organizations world-wide to support pre-clinical and clinical studies. We also support our clients for preparation of Chemistry, Manufacturing and Controls (CMC) ...
Manufactured by:AOBiome Therapeutic, LLC based inCambridge, MASSACHUSETTS (USA)
We have completed six Phase 2 clinical programs and multiple pre-clinical programs. Over 1,000 patients have been enrolled in our clinical trials since 2016. All of those patients except for 28 in our open label pediatric study have been enrolled in randomized double-blind placebo controlled ...
Manufactured by:Novo Nordisk A/S based inBagsværd, DENMARK
Our proprietary GalXC technology leverages a naturally occurring biologic process, ribonucleic acid interference, RNAi, to create therapies that silence disease-causing genes. This platform enables Dicerna to create molecules that can effectively interfere with the RNAi processes that lead to defective or misregulated proteins that cause disease. ...
by:Hillhurst Biopharmaceuticals, Inc. based inSan Diego, CALIFORNIA (USA)
Therapeutic medical gases have the potential to address a wide spectrum of diseases, but have been limited by inhaled delivery, which for conscious patients is inaccurate in dosing, potentially unsafe, and highly intrusive. Hillhurst’s GLASS technology platform is designed to address the challenges of inhaled gases by enabling liquid delivery of therapeutic gases to ensure accurate dosing ...